+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation



Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation



Official Gazette of the United States Patent & Trademark Office Patents 1231(4), Feb 22



The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

(PDF emailed within 1 workday: $29.90)

Accession: 035985975

Download citation: RISBibTeXText


Related references

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation. Official Gazette of the United States Patent & Trademark Office Patents 1232(4), Mar 28, 2000

Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation. Official Gazette of the United States Patent & Trademark Office Patents 1268(3), Mar 18, 2003

Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease. Official Gazette of the United States Patent & Trademark Office Patents 1253(3), Dec 18, 2001

Pregnancy in sickle cell, anemia, sickle cell-hemoglobin C disease, and variants thereof. American Journal of Obstetrics and Gynecology 77(6): 1312-1323, 1959

Sickle Cell Disease Subjects Have a Distinct Abnormal Autonomic Phenotype Characterized by Peripheral Vasoconstriction With Blunted Cardiac Response to Head-Up Tilt. Frontiers in Physiology 10: 381, 2019

Composition and method containing products extracted from Commiphora sp for prevention and treatment of abnormal cell growth and proliferation in inflammation, neoplasia and cardiovascular disease. Official Gazette of the United States Patent & Trademark Office Patents 1261(3), Aug 20, 2002

Abnormal growth patterns in sickle cell disease and sickle cell trait. Pediatric Research: 354-126, 1973

Sickle cell disease: a continuing clinical and research dilemma: Bone marrow transplantation for sickle cell disease Walters, M.C. et al. (1996) New Engl. J. Med. 335, 369376 Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial Ferster, A. et al. (1996) Blood 88, 19601961. Molecular Medicine Today 2(11): 450-451, 1996

The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. Therapeutic Apheresis 6(1): 24-31, 2002

Prevention of red cell dehydration: a possible new treatment for sickle cell disease. Pediatric Pathology and Molecular Medicine 20(1): 15-25, 2003

Prevention of red cell dehydration: A possible new treatment for sickle cell disease. Pediatric Pathology & Molecular Medicine 20(1): 15-25, January-February, 2001

Prevention of sickle cell disease: observations on females with the sickle cell trait from the Manchester project, Jamaica. Journal of Community Genetics 7(2): 127-132, 2015

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease. Blood 91(12): 4472-4479, 1998

Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease. Haematologica 94(8): 1060-1065, 2009

Triaryl methane compounds and their use in the treatment of diarrhea and scours. Official Gazette of the United States Patent & Trademark Office Patents 1265(3), Dec 17, 2002